Skip to content
    AMR Action Fund logo

    AMR Action Fund

    Boston, Massachusetts, United StatesFounded 2020
    www.amractionfund.comLinkedIn
    Biotech & Life SciencesHealthcare

    The AMR Action Fund is the world's largest venture capital fund dedicated to investing in urgently needed antimicrobial therapeutics. It makes equity investments in small and mid-size biotech companies developing treatments for patients suffering from life-threatening antimicrobial-resistant infections.

    65% of their portfolio is in Biotech & Life Sciences. Deal activity increased 300% year-over-year (4 deals in the last 12 months). Average disclosed round size is $44.3M (across 12 rounds with reported amounts).

    Find people at AMR Action Fund on Goldilocks AI

    Portfolio

    16

    Fund Size

    $1B

    Top Stage

    Series B

    Last 12 Mo

    4

    Team

    CS

    Chris Sweeney, MSJ

    Executive Director, Communications and Media Relations

    DP

    Deepali Patel, MPH

    Director of International Policy

    JG

    Junjun Gao, PhD

    Principal

    CL

    Carly Levine, PhD

    Senior Associate

    HR

    Henni-Karoliina Ropponen, PhD

    Venture Associate

    IS

    Isabella Santi, PhD

    Venture Associate

    MH

    Martin Heidecker, PhD, MBA

    Chief Investment Officer

    CR

    Corinna Ruppli

    Office Manager

    DH

    David Hellmuth, JD

    Chief Legal Officer, Chief Compliance Officer, Chief Operating Officer

    DM

    Dorothy Maloney

    Compliance Officer

    HS

    Henry Skinner, PhD, MBE, MJur

    Chief Executive Officer

    JV

    John Vancura, MBA

    Chief Financial Officer

    Portfolio Breakdown

    Stage Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    20 investments
    CompanyRoundAmountDate
    Tennor Therapeutics logoTennor TherapeuticsSeries E—Sep 2026
    TTennorSeries E$41MSep 2026
    Trellis Bioscience logoTrellis BioscienceSeries C$9MJul 2026
    Centauri Therapeutics logoCentauri TherapeuticsSeries A—Feb 2026
    Tennor Therapeutics logoTennor TherapeuticsSeries E—Oct 2024
    Elion Therapeutics logoElion TherapeuticsSeries B$81MJun 2024
    SSfunga TherapeuticsSeries B$81MJun 2024
    BBioVersysSeries C$32.6MMay 2024
    FF2GSeries H$100MJan 2024
    Vedanta Biosciences logoVedanta BiosciencesSeries D$40MJan 2024
    Antabio logoAntabioSeed—Dec 2023
    Peptilogics logoPeptilogicsSeries B$35.4MDec 2020
    Vedanta Biosciences logoVedanta BiosciencesSeries C$16.6MSep 2019
    Antabio logoAntabioSeries B—Jul 2017
    Pattern Bioscience logoPattern BioscienceUnknown$28.7M—
    CCentauriSeries A——
    TTelum TherapeuticsSeries A——
    TTennorSeries B$25M—
    VVenatorx PharmaceuticalsSeries C——
    AAdaptive Phage TherapeuticsSeries B$40.8M—

    Top Co-Investors

    Deerfield3 shared
    Illinois Ventures2 shared
    WuXi Healthcare Ventures2 shared
    QUAD Investment Management2 shared
    Korea Investment Partners2 shared
    Seventure Partners2 shared
    Revelation Partners2 shared
    SV Investment Corporation2 shared
    European Innovation Council (EIC)2 shared
    Tomcat2 shared
    Boehringer Ingelheim Venture Fund1 shared
    Cowen Healthcare Investments1 shared
    Forbion1 shared
    Morningside1 shared
    Sofinnova Partners1 shared
    Sectoral Asset Management1 shared
    Novo Capital1 shared
    Valor Equity Partners1 shared
    K2 HealthVentures1 shared
    Salica Investments1 shared

    Last updated: 20 October 2026